Cefminox versus Ceftriaxone plus Metronidazole for conservative treatment of acute cholecystitis; a prospective randomised controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180514001

Enrollment

140

Registered

2018-05-14

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cholecystitis Acute cholecystitis Conservative treatment Intravenous antibiotics

Interventions

Give Cefminox to patients with acute cholecystitis,Give Ceftriazone plus Metronidazole to patients with acute cholecystitis

Active Comparator Drug,Active Comparator Drug

Cefminox,Ceftriazone plus metronidazole

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: - Age 15-75 years old - Patients diagnose acute cholecystitis - Not allergic to Cephalosporin or Metronidazole

Exclusion criteria

Exclusion criteria: - Patients with acute cholecystitis grade III - Patients with acute cholangitis - Patients who receive ERCP - Malignancy - Pregnancy - Immunodeficiency

Design outcomes

Primary

Measure	Time frame
Response to antibiotic treatment Before discharge from hospital No fever, No abdominal pain, Appetite	—

Secondary

Measure	Time frame
Side effect Before discharge from hospital Patient have side effect from medicine or not (allergy, rash, N/V, anaphylactic shock),Recurrence Until surgery Patient back to the hospital after discharge	—

Contacts

Public ContactAkkaraphorn Deeprasertvit

Police General Hospital

deeprasertvit@hotmail.com093-5326669

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026